The Effect of Royal Jelly on Gene Expression of Some Immune Factors in People Infected with Hepatitis B

Investigating the Effect of Royal Jelly on the expression of Some Members of S100, Apoptosis, Inflammasomes and Chemokines Families in the Patients with Chronic HBV Infections

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210620051640N1

Enrollment

Registered

2021-08-26

Start date

2021-09-10

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B. Chronic viral hepatitis

Interventions

In this study, 50 Hepatitis B virus infected patients will be treated with oral administration of royal jelly at a rate of one gram per day for a month. Royal jelly will be used as an intervention age

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Infected with Hepatitis B for more than six months

Exclusion criteria

Exclusion criteria: Infected by other viruses Suffering from immune related diseases Receiving drugs that affect the immune system

Design outcomes

Primary

Measure	Time frame
Gene expression of some molecules of S100 families, apoptosis, inflammation and chemokines is measured in patients with hepatitis B before and after oral administration of Royal Jelly. Timepoint: Before and after taking Royal Jelly orally. Method of measurement: Real time PCR assay.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Bahaadin Beygi

Islamic Azad University

beygi_morteza@yahoo.com+98 34 3132 1376

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026